Metacognitive Therapy and Work Interventions for Patients on Sick Leave Due to Common Mental Disorders

Metacognitive Therapy and Work Interventions for Patients on Sick Leave Due to Common Mental Disorders: A Randomized Waiting List Controlled Trial

Common mental health disorders such as anxiety and depression are leading causes of sickness absence and disability in Norway. Despite tremendous costs for individual and society, effective treatment is lacking. Mental health interventions do not typically target work situation, despite its importance for patient well-being. On a policy level, effective measures are impeded by a paucity of scientific data, and programs designed to address the issue such as Faster Return to Work ("Raskere tilbake") lack evaluation. The present project will test the effectiveness of Metacognitive therapy and work-focused interventions for reducing sick leave in patients with common mental disorders.

Study Overview

• Status: Recruiting
• Conditions: Depression; Anxiety
• Intervention / Treatment: Behavioral: Metacognitive therapy and work-focused interventions; Other: Waiting list

Detailed Description

Common mental health disorders (CMD) such as anxiety and depression are leading contributors to the global burden of disease , generating substantial costs for societies in reduced productivity and increased benefit pay outs. In 2010, the worldwide cost of mental health disability was estimated at US$2.5-8.5 trillion in lost output, and the sum is projected to double by 2030 unless effective policy measures are implemented. For middle- and high-income countries, 30-50 % of disability applications stem from mental health issues, and the proportion is likely greater among the younger part of the work force. In Europe, depression is responsible for 13.7 % of all years lived with disability, and anxiety disorders likely have similar impact. Mental health issues are among the leading causes of disability and early retirement across the European region.

For affected individuals, anxiety and depression reduces quality of life, decreases functioning and increases the risk of further health problems. Sick leave is often used for adults with CMD, but may not always be helpful. Avoidance and isolation are behavioural strategies that maintain anxiety and depression. Absenteeism from work, an important social arena, may strengthen this behaviour, impeding recovery. Even when controlling for the impact of ill health, short term sick leave may in itself increase the risk of future long term absence. In addition, employment rates are 10-15% lower for people with mental ill health than the rest of the population. Exclusion from the work force is in turn associated with poorer mental health, and can heighten the risk of futures depression and even suicide. The relationship between CMD and reduced work-participation is therefore likely bidirectional, and sick leave may not work as intended despite its high cost for society.

The individual and societal burden from sick leave and mental health represents a key policy challenge on the global agenda and the need for efficient measures is urgent. Norway exemplifies this urgent need as expenditure on disability and sickness absence totals 5 % of GDP, by far the highest in the OECD. Efforts have been made to address the issue through several policy initiatives, such as the nationwide Faster Return to Work (FRW) program. The program facilitates buying treatment from different actors to reduce waiting times and thus potentially the duration of sick leave. The impact of the program is uncertain, as little research has been done on its efficacy. Scientific data on Norwegian sick leave follow up is mostly absent. Despite the magnitude of the challenge, there is a clear knowledge gap.

Investment in sick leave follow up has not been equally distributed amongst patient groups. Sixty per cent of all working days lost to disability or sick leave are due to mental health issues and musculoskeletal complaints. Sick leave due to CMD is growing. When caused by mental health issues, disability pension is awarded on average nine years earlier than for somatic reasons, resulting in more working years lost to disability. Though prevalent in the statistics, few CMD patients on sick leave receive treatment. Only 1.4 % of employees on sick leave are referred to specialized mental health treatment. As many as one in three people awarded disability pension for mental illness have never received any form of treatment prior to disability being granted. This shows a severe under-referral and under-treatment for this patient group despite being responsible for the majority of sick leave and disability costs.

A more targeted approach, integrating work-focused interventions with effective CMD treatment is needed for this patient group. Two recent studies have examined such an approach. In the Netherlands, Lagerveld and Blonk conducted a randomized controlled trial where 168 patients on sick leave due to CMD received either cognitive behavioural therapy (CBT), or CBT with an integrated work-focused intervention. Their results showed a 20 % decrease in sickness absence for patients receiving the work-focused intervention, while maintaining effective symptom reduction. In Germany, similar results were found with a smaller sample size. A multicentre trial in Norway looked at registry data for 1193 CMD patients receiving a variation of work-specific interventions, showing a clear reduction in sick leave and disability. Integrated work-focused treatment for CMD is thus a promising avenue of research.

Metacognitive therapy (MCT) is a treatment based on more recent theoretical developments. It has shown excellent results for anxiety and depression, and the treatment protocol for generalized anxiety disorder and social phobia is recommended in the NICE guidelines. Rather than challenging and changing specific thought content (CBT), metacognitive treatment aims to change and challenge maladaptive cognitive processes, among these rumination and worry, which are key components in CMD and sick leave.

The study will be a randomized controlled trial. Participants will be persons with a primary diagnosis of common mental disorders, anxiety and depression. Experienced independent diagnosticians will assess all patients by using structural interviews MINI (MINI International Neuropsychiatric Interview).

All patients will be randomized in blocks to two groups in order to compare the following conditions: MCT and work-focused interventions, and a wait list control condition. After the waiting period of either 8 or 12 weeks, the patients in the wait-list condition will be allocated to the treatment condition. Both between-subjects and within-subjects comparisons will be conducted.

Questions that will be addressed are:

1. MCT and work-focused interventions will be superior to the wait-list condition in make participants return to work
2. Which changes in predictors related to treatment predict return to work
3. MCT and work-focused interventions will be superior to the wait-list condition for improving mental health
4. MCT and work-focused interventions will be more cost-efficient than the wait-list condition
5. Evaluate the sustainability of return to work for patients on sick leave due to common mental disorders after MCT and work-focused interventions
6. Examine impact of different potential prognostic factors on work function, both at the end of treatment and at one year follow-up.
7. If the effect of MCT and work-focused interventions will sustain one year after the end of therapy
8. Explore if patients will have reduced use of sick leave in the four years following after treatment compared to the two years prior to treatment based on register data.

The meta-cognitive treatment program is based on Wells' manual. The work-focused intervention is based on an adopted Norwegian version of Lagerveld and Blonk. The interventions are run in parallel. The patients who are receiving MCT and work-focused interventions will be treated up to maximum 12 sessions, with weekly session of 45-60 minute duration.

The treatment will be administered according to the originators published treatment protocols for MCT.

1. All patients referred to the clinic will be consecutively assessed at intake (MINI). Based on diagnosis and criteria for inclusion and exclusion, the patients will be asked to volunteer to participate in the study and confirm by signing a form of consent.
2. Patients will be randomized to one of the two conditions.
3. Patients will be asked to self-rate symptoms on a battery of self-report questionnaires.
4. Work-focused meta-cognitive therapy will be given to patients in group 1, while group 2 is a waiting list control. Waiting list controls will be rated but not treated and will wait for treatment for either 8 or 12 weeks.
5. After waiting they will be transferred to the treatment group.
6. The patients will be assessed prior to treatment, by at end of treatment weeks in treatment, and at six months and at, one and two years of follow-up.
7. Reassessment of the diagnosis and symptom severity is made by post-treatment.

Criteria for recovery will be: Jacobsen criteria of a minimum change and patients crossing the cut-off point on two measures: The BDI and BAI. Other outcome measures will include:

• Reduction of depressive symptoms as measured by self-report questionnaires
• Number of patients with no diagnosis based on MINI after treatment
• Relapse rate during six months and at, one year follow-up

A comparison between the two groups of patients will be conducted at post-treatment. Follow-up data will be analysed based on 6 month and at one year of follow up for the treatment condition with self-report and a four year follow-up with register data. A within group analyses will be conducted in order to estimate effect sizes and significant clinical change estimates.

Participants will be randomized in patients divided on three conditions in a 1:2 ratio. One factors are controlled for in the randomization, namely, gender. A computer program provided by NTNU WebCRF will generate the randomization list.

• Study Type: Interventional
• Enrollment (Anticipated): 240
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Odin Hjemdal, prof; Phone Number: 0047 73597889; Email: odin.hjemdal@ntnu.no

Study Locations

• Norway
  • Oslo, Norway
    • Recruiting
    • Poliklinikken Raskere Tilbake, Diakonhjemmet Sykehus
    • Contact: Odin Hjemdal, phd prof; Email: odin.hjemdal@ntnu.no

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• on sick leave either partial or full, due to
• clinically relevant level of anxiety and depression, and
• eligible for work-related sick leave pay outs
• given consent

Exclusion Criteria:

• Serious mental illness (such as bipolar disorder or schizophrenia)
• Substance abuse
• Cluster A and B personality disorder

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Work-focused metacognitive therapy	Behavioral: Metacognitive therapy and work-focused interventions; Metacognitive therapy and work-focused interventions, up to maximum 12 sessions, with weekly session of 45-60 minute duration. The metacognitive treatment program is based on Wells' manual. The work-focused intervention is based on Lagerveld and Blonk. The interventions are run in parallel.
OTHER: Waiting list	Behavioral: Metacognitive therapy and work-focused interventions; Metacognitive therapy and work-focused interventions, up to maximum 12 sessions, with weekly session of 45-60 minute duration. The metacognitive treatment program is based on Wells' manual. The work-focused intervention is based on Lagerveld and Blonk. The interventions are run in parallel.; Other: Waiting list; Waiting list

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in degree of sick leave	data from National registers	From 2 years prior to intervention - to 4 years after intervention
Changes in degree of sick leave	data from patients self-report	From 2 years prior to intervention - to 4 years after intervention
Changes in anxiety symptoms	Changes in depressive symptoms measured by Beck Anxiety Inventory (BAI)	From pre treatment, to post treatment (12 weeks), 6 months and 1 year follow-up
Changes in depressive symptoms	Changes in depressive symptoms measured by Beck Depression Inventory II (BDI-II)	From pre treatment, to post treatment (12 weeks), 6 months 1 year follow-up

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in metacognitions	Changes in metacognitions symptoms measured by the Metacognitions Questionnaire 30 (MCQ-30)	From pre treatment, to post treatment (12 weeks), 6 months and 1 year follow-up
Changes in subjective health complaints	Changes in symptoms measured by Subjective Health Complaints	From pre treatment, to post treatment (12 weeks), 6 months and 1 year follow-up
Changes in bullying and victimisation at work	Changes in measured Negative Acts Questionnaire	From pre treatment, to post treatment (12 weeks), 6 months and 1 year follow-up
Changes in self-efficacy	Changes measured with Return to work self-efficacy	From pre treatment, to post treatment (12 weeks), 6 months and 1 year follow-up
Changes in resilience	Changes measured with The resilience scale for adults (RSA)	From pre treatment, to post treatment (12 weeks), 6 months and 1 year follow-up
Changes in quality of life	Changes measured with EQ-5D-5L	From pre treatment, to post treatment (12 weeks), 6 months and 1 year follow-up
MINI - diagnostic interview	Diagnostic evaluations using MINI - International Neuropsychiatric Interview	From pre treatment, to post treatment (12 weeks)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Secondary analysis related to the onset of Covid-19	Sub-analyses taking into consideration the onset of Covid-19 in Norway by mid March 2020	From pre treatment, to post treatment (12 weeks), 6 months and 1 year follow-up

Collaborators and Investigators

• Sponsor: Norwegian University of Science and Technology
• Collaborators: Diakonhjemmet Hospital
• Investigators: Principal Investigator: Odin Hjemdal, prof, Norwegian University of Science and Technology; Study Chair: Ragne GH Gjengedal, Diakonhjemmet Hospital

Publications and helpful links

General Publications

• Sandin K, Gjengedal RGH, Osnes K, Hannisdal M, Berge T, Leversen JSR, Rov LG, Reme SE, Lagerveld S, Blonk R, Nordahl HM, Shields G, Wells A, Hjemdal O. Metacognitive therapy and work-focused interventions for patients on sick leave due to anxiety and depression: study protocol for a randomised controlled wait-list trial. Trials. 2021 Nov 27;22(1):854. doi: 10.1186/s13063-021-05822-4. Erratum In: Trials. 2021 Dec 19;22(1):941.

Study record dates

Study Major Dates

• Study Start (ACTUAL): October 31, 2017
• Primary Completion (ANTICIPATED): April 1, 2023
• Study Completion (ANTICIPATED): April 1, 2023

Study Registration Dates

• First Submitted: September 29, 2017
• First Submitted That Met QC Criteria: September 29, 2017
• First Posted (ACTUAL): October 4, 2017

Study Record Updates

• Last Update Posted (ACTUAL): September 19, 2022
• Last Update Submitted That Met QC Criteria: September 16, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Keywords: Metacognitive therapy; Occupational Health Services; Sick leave; Work focused interventions
• Additional Relevant MeSH Terms: Schizophrenia Spectrum and Other Psychotic Disorders; Psychotic Disorders; Mental Disorders
• Other Study ID Numbers: 2015/1794

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No